INT301 (implied)
Peanut Allergy
Pre-clinicalActive
Key Facts
About Intrommune Therapeutics
Intrommune Therapeutics is a clinical-stage biotech developing a disruptive drug delivery platform for food allergy immunotherapy. Its lead program, INT301, encapsulates allergenic proteins in a toothpaste, enabling daily treatment through routine brushing to desensitize patients via the oral mucosa. The company is targeting a large and growing unmet medical need with a treatment designed to improve adherence and quality of life over current burdensome options. Led by a management team with legal, financial, and clinical expertise, Intrommune is advancing its OMIT platform through clinical development.
View full company profileTherapeutic Areas
Other Peanut Allergy Drugs
| Drug | Company | Phase |
|---|---|---|
| INP20 | InnoUp | Clinical |
| Food Allergy Program | Hal Allergy | Clinical Development |
| Peanut allergy program | Desentum | Unknown |
| Peanut Oral Immunotherapy | Camallergy | Phase 2 |
| VLP Peanut (VLP-p) | Allergy Therapeutics | Phase II |